Monitoring early tumor response to drug therapy with diffuse optical tomography

Molly L. Flexman, Fotios Vlachos, Hyun Keol Kim, Shashank R. Sirsi, Jianzhong Huang, Sonia L. Hernandez, Tessa B. Johung, Jeffrey W. Gander, Ari R. Reichstein, Brooke S. Lampl, Antai Wang, Mark A. Borden, Darrell J. Yamashiro, Jessica J. Kandel, Andreas H. Hielscher

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy - thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.

Original languageEnglish (US)
Article number016014
JournalJournal of Biomedical Optics
Volume17
Issue number1
DOIs
StatePublished - Jan 1 2012

Fingerprint

Drug therapy
Optical tomography
chemotherapy
Tumors
tumors
tomography
Monitoring
Imaging techniques
Hemoglobin
hemoglobin
therapy
Hemoglobins
drugs
transponders
animal models
Magnetic resonance
Lectins
Heterografts
toxicity
Vascular Endothelial Growth Factor A

Keywords

  • Angiogenesis
  • Avastin®
  • Bevacizumab
  • Cancer imaging
  • Diffuse optical imaging
  • Diffuse optical tomography
  • Magnetic resonance imaging
  • Therapy response

ASJC Scopus subject areas

  • Electronic, Optical and Magnetic Materials
  • Atomic and Molecular Physics, and Optics
  • Biomaterials
  • Biomedical Engineering

Cite this

Flexman, M. L., Vlachos, F., Kim, H. K., Sirsi, S. R., Huang, J., Hernandez, S. L., ... Hielscher, A. H. (2012). Monitoring early tumor response to drug therapy with diffuse optical tomography. Journal of Biomedical Optics, 17(1), [016014]. https://doi.org/10.1117/1.JBO.17.1.016014

Monitoring early tumor response to drug therapy with diffuse optical tomography. / Flexman, Molly L.; Vlachos, Fotios; Kim, Hyun Keol; Sirsi, Shashank R.; Huang, Jianzhong; Hernandez, Sonia L.; Johung, Tessa B.; Gander, Jeffrey W.; Reichstein, Ari R.; Lampl, Brooke S.; Wang, Antai; Borden, Mark A.; Yamashiro, Darrell J.; Kandel, Jessica J.; Hielscher, Andreas H.

In: Journal of Biomedical Optics, Vol. 17, No. 1, 016014, 01.01.2012.

Research output: Contribution to journalArticle

Flexman, ML, Vlachos, F, Kim, HK, Sirsi, SR, Huang, J, Hernandez, SL, Johung, TB, Gander, JW, Reichstein, AR, Lampl, BS, Wang, A, Borden, MA, Yamashiro, DJ, Kandel, JJ & Hielscher, AH 2012, 'Monitoring early tumor response to drug therapy with diffuse optical tomography', Journal of Biomedical Optics, vol. 17, no. 1, 016014. https://doi.org/10.1117/1.JBO.17.1.016014
Flexman, Molly L. ; Vlachos, Fotios ; Kim, Hyun Keol ; Sirsi, Shashank R. ; Huang, Jianzhong ; Hernandez, Sonia L. ; Johung, Tessa B. ; Gander, Jeffrey W. ; Reichstein, Ari R. ; Lampl, Brooke S. ; Wang, Antai ; Borden, Mark A. ; Yamashiro, Darrell J. ; Kandel, Jessica J. ; Hielscher, Andreas H. / Monitoring early tumor response to drug therapy with diffuse optical tomography. In: Journal of Biomedical Optics. 2012 ; Vol. 17, No. 1.
@article{de881f01ac914a8fb2f3e97d5297b4e3,
title = "Monitoring early tumor response to drug therapy with diffuse optical tomography",
abstract = "Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy - thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.",
keywords = "Angiogenesis, Avastin{\circledR}, Bevacizumab, Cancer imaging, Diffuse optical imaging, Diffuse optical tomography, Magnetic resonance imaging, Therapy response",
author = "Flexman, {Molly L.} and Fotios Vlachos and Kim, {Hyun Keol} and Sirsi, {Shashank R.} and Jianzhong Huang and Hernandez, {Sonia L.} and Johung, {Tessa B.} and Gander, {Jeffrey W.} and Reichstein, {Ari R.} and Lampl, {Brooke S.} and Antai Wang and Borden, {Mark A.} and Yamashiro, {Darrell J.} and Kandel, {Jessica J.} and Hielscher, {Andreas H.}",
year = "2012",
month = "1",
day = "1",
doi = "10.1117/1.JBO.17.1.016014",
language = "English (US)",
volume = "17",
journal = "Journal of Biomedical Optics",
issn = "1083-3668",
publisher = "SPIE",
number = "1",

}

TY - JOUR

T1 - Monitoring early tumor response to drug therapy with diffuse optical tomography

AU - Flexman, Molly L.

AU - Vlachos, Fotios

AU - Kim, Hyun Keol

AU - Sirsi, Shashank R.

AU - Huang, Jianzhong

AU - Hernandez, Sonia L.

AU - Johung, Tessa B.

AU - Gander, Jeffrey W.

AU - Reichstein, Ari R.

AU - Lampl, Brooke S.

AU - Wang, Antai

AU - Borden, Mark A.

AU - Yamashiro, Darrell J.

AU - Kandel, Jessica J.

AU - Hielscher, Andreas H.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy - thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.

AB - Although anti-angiogenic agents have shown promise as cancer therapeutics, their efficacy varies between tumor types and individual patients. Providing patient-specific metrics through rapid noninvasive imaging can help tailor drug treatment by optimizing dosages, timing of drug cycles, and duration of therapy - thereby reducing toxicity and cost and improving patient outcome. Diffuse optical tomography (DOT) is a noninvasive three-dimensional imaging modality that has been shown to capture physiologic changes in tumors through visualization of oxygenated, deoxygenated, and total hemoglobin concentrations, using non-ionizing radiation with near-infrared light. We employed a small animal model to ascertain if tumor response to bevacizumab (BV), an anti-angiogenic agent that targets vascular endothelial growth factor (VEGF), could be detected at early time points using DOT. We detected a significant decrease in total hemoglobin levels as soon as one day after BV treatment in responder xenograft tumors (SK-NEP-1), but not in SK-NEP-1 control tumors or in non-responder control or BV-treated NGP tumors. These results are confirmed by magnetic resonance imaging T2 relaxometry and lectin perfusion studies. Noninvasive DOT imaging may allow for earlier and more effective control of anti-angiogenic therapy.

KW - Angiogenesis

KW - Avastin®

KW - Bevacizumab

KW - Cancer imaging

KW - Diffuse optical imaging

KW - Diffuse optical tomography

KW - Magnetic resonance imaging

KW - Therapy response

UR - http://www.scopus.com/inward/record.url?scp=84861426451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861426451&partnerID=8YFLogxK

U2 - 10.1117/1.JBO.17.1.016014

DO - 10.1117/1.JBO.17.1.016014

M3 - Article

C2 - 22352664

AN - SCOPUS:84861426451

VL - 17

JO - Journal of Biomedical Optics

JF - Journal of Biomedical Optics

SN - 1083-3668

IS - 1

M1 - 016014

ER -